Table 1.
Baseline characteristics of HIV-infected antiretroviral therapy (ART)-suppressed study participants.
| Disulfiram Dose Cohort Characteristics |
500 mg N = 10 |
1000 mg N = 10 |
2000 mg N = 10 |
Total N = 30 |
|---|---|---|---|---|
| Gender (male vs. MTF transgender) a | 9 (90%) | 9 (90%) | 10 (100%) | 28 (98%) |
| Age (years) b | 54 (34 – 63) | 54 (40 – 65) | 54 (26 – 67) | 54 (26 – 67) |
| Pre-ART HIV RNA (log10 copies/mL) b | 4.2 (3.0 – 5.4) | 4.9 (4.7 – 5.9) | 4.8 (4.2 – 5.6) | 4.8 (3.0 – 5.9) |
| Nadir CD4+ T cell count (cells/mm3) b | 182 (2 – 380) | 96 (7 – 680) | 132 (1 – 666) | 149 (1 – 680) |
| Duration of ART (years) b | 5 (3 – 15) | 13 (3 – 29) | 10 (2 – 19) | 8 (2 – 29) |
| Proximal CD4+ T cell count (cells/mm3) b, c | 560 (401 – 1180) | 610 (390 – 1137) | 527 (414 – 1022) | 582 (390 – 1180) |
| Antiretroviral regimen (non-NRTI drug) a | ||||
| PI | 5 (50%) | 4 (40%) | 3 (30%) | 12 (40%) |
| NNRTI | 5 (50%) | 4 (40%) | 6 (60%) | 15 (50%) |
| INI | 0 | 2 (20%) | 1 (10%) | 3 (10%) |
| CA-US HIV RNA (copies/106 CD4+ T cells) b, d | 99 (2.2–557) | 69 (6.7–4111) | 113 (9.7–1598) | 99 (2.2–4111) |
| Plasma HIV RNA (copies/mL) b, d | 5.7 (0–25) | 2.6 (0–10) | 0.87 (0–12) | 2.3 (0–25) |
Abbreviations: MTF = male-to-female; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; INI = integrase inhibitor; CA-US HIV RNA = cell-associated HIV RNA.
a
Frequency and percent.
b
Median with minimum and maximum range.
c
“Proximal” refers to most recent CD4+ T cell count.
d
Summary statistics are shown for the mean of 3 baseline values as described in Elliott et. al., Lancet HIV, 2015 (19).